Immunotoxin Market Report 2026

Immunotoxin Market Overview

• Immunotoxin market size has reached to $66 billion in 2025 • Expected to grow to $96.77 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: Impact of Increasing Breast Cancer Incidence on the Immunotoxin Market • Market Trend: FDA Approves First ADC For Metastatic Or Recurrent Cervical Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Immunotoxin Market?

Immunotoxins are bioengineered proteins that combine an antibody or antibody fragment with a toxin to selectively target and kill specific cells, such as cancer cells. The antibody portion of the immunotoxin binds to a specific antigen on the surface of the target cell, delivering the toxin directly to the cell. Immunotoxins are designed to spare healthy cells and tissues, minimizing side effects compared to traditional chemotherapy. The main types of immunotoxins include anthrax-based toxins, diphtheria toxin (DT) and derivatives, pseudomonas exotoxin (PE) and derivatives, ribosome-inactivating proteins-based immunotoxins, ribonucleases-based immunotoxins, and others. Anthrax-based toxins are substances developed by bacteria that cause anthrax, a serious illness. They are used in various applications, such as solid tumors, leukemias, and others, by several end users, including hospitals and clinics, cancer and radiation therapy centers, research labs, and others.

What Is The Immunotoxin Market Growth Forecast?

The immunotoxin market size is expected to see strong growth in the next few years. It will grow to $96.77 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growing demand for precision oncology treatments, expansion of immunotherapy pipelines, increasing investment in biologics-based cancer drugs, rising prevalence of treatment-resistant cancers, continued innovation in protein engineering technologies. Major trends in the forecast period include rising development of target-specific immunotoxins for cancer therapy, growing focus on reducing off-target toxicity and immunogenicity, increasing use of immunotoxins in hematological malignancies, expansion of clinical research in next-generation immunotoxin constructs, continued exploration of combination immunotoxin therapies.

Global Immunotoxin Market Segmentation

1) By Type: Anthrax Based Toxins, Diphtheria Toxin (DT) And Derivatives, Pseudomonas Exotoxin (PE) And Derivatives, Ribosome Inactivating Proteins Based Immunotoxins, Ribonucleases-Based Immunotoxins, Other Types 2) By Application: Solid Tumors, Leukemias, Other Applications 3) By End User: Hospitals And Clinics, Cancer And Radiation Therapy Centers, Research Labs, Other End-Users Subsegments: 1) By Anthrax-Based Toxins: Anthrax Lethal Toxin, Anthrax Protective Antigen 2) By Diphtheria Toxin (DT) And Derivatives: Diphtheria Toxin, DT Fragment-Based Immunotoxins 3) By Pseudomonas Exotoxin (PE) And Derivatives: PE38-Based Immunotoxins, PE-Based Fusion Proteins 4) By Ribosome Inactivating Proteins-Based Immunotoxins: Ricin-Based Immunotoxins, Gelonin-Based Immunotoxins 5) By Ribonucleases-Based Immunotoxins: Onconase-Based Immunotoxins, Binase-Based Immunotoxins 6) By Other Types: Shiga Toxin-Based Immunotoxins, Other Toxin-Based Immunotoxins

What Is The Driver Of The Immunotoxin Market?

The increasing incidence of breast cancer is expected to propel the growth of the immunotoxin market going forward. Breast cancer refers to a malignant tumor that develops in the cells of the breast, most commonly in the ducts or lobules. The incidence of breast cancer is rising due to improved screening programs, lifestyle-related risk factors, and increasing life expectancy. The immunotoxin market supports breast cancer treatment by providing targeted therapies that selectively kill cancer cells while minimizing damage to healthy tissue, thereby reducing side effects compared to traditional chemotherapy. For instance, in January 2025, according to the National Breast Cancer Foundation, a US-based organization, one in every eight women in the United States will be diagnosed with breast cancer during her lifetime. In 2024, approximately 310,720 women and 2,800 men are expected to be diagnosed with invasive breast cancer. Therefore, the increasing incidence of breast cancer is driving the growth of the immunotoxin industry.

Key Players In The Global Immunotoxin Market

Major companies operating in the immunotoxin market are ImmunoGen Inc., Molecular Templates Inc., Mersana Therapeutics, Seagen Inc., MacroGenics Inc., Sutro Biopharma Inc., Celldex Therapeutics, CytImmune Sciences Inc., Pfizer Inc., Roche Holding AG, AbbVie Inc., Bristol Myers Squibb, AstraZeneca plc, Merck KGaA, BioNTech SE, Ipsen Pharma, Innate Pharma Inc., GenScript, Thermo Fisher Scientific Inc., Enzo Life Sciences Inc.

Global Immunotoxin Market Trends and Insights

Major companies operating in the immunotoxin market are focusing on developing advanced antibody-drug conjugates (ADCs) to enhance the specificity and effectiveness of cancer treatment while reducing harm to healthy tissues. ADCs refer to targeted biopharmaceutical therapies composed of a monoclonal antibody linked to a cytotoxic drug, enabling precise delivery of the toxic payload to cancer cells that express a specific antigen and improving therapeutic outcomes compared to conventional chemotherapy. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical company, and Genmab A/S, a Denmark-based biotechnology company, received full U.S. FDA approval for TIVDAK, an antibody-drug conjugate designed for patients with metastatic or recurrent cervical cancer, featuring a monomethyl auristatin E payload that disrupts microtubules to induce cancer-cell death and demonstrating statistically significant improvements in overall survival, establishing it as a promising targeted treatment option for advanced cervical cancer.

What Are Latest Mergers And Acquisitions In The Immunotoxin Market?

In February 2024, AbbVie, a US-based biopharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. This acquisition strengthens AbbVie’s oncology portfolio by integrating ImmunoGen’s innovative antibody-drug conjugate (ADC) technology to advance the development of targeted cancer therapies. It further enhances AbbVie’s strategic position in next-generation oncology treatments by expanding its pipeline with clinically validated ADC assets. ImmunoGen Inc. is a US-based biotechnology company that develops immunotoxins.

Regional Insights

North America was the largest region in the immunotoxin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Immunotoxin Market?

The immunotoxin market consists of sales of linker molecules, expression systems, antibody or antibody fragments, and cytotoxic agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Immunotoxin Market Report 2026?

The immunotoxin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the immunotoxin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.